TY - JOUR T1 - HLA-A*01:01 allele vanishing in COVID-19 patients population associated with non-structural epitope abundance in CD8<sup>+</sup> T-cell repertoire JF - medRxiv DO - 10.1101/2022.07.05.22277214 SP - 2022.07.05.22277214 AU - Maxim Shkurnikov AU - Stepan Nersisyan AU - Darya Averinskaya AU - Milena Chekova AU - Fedor Polyakov AU - Aleksei Titov AU - Dmitriy Doroshenko AU - Valery Vechorko AU - Alexander Tonevitsky Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/08/12/2022.07.05.22277214.abstract N2 - In mid-2021, the SARS-CoV-2 Delta variant caused the third wave of the COVID-19 pandemic in several countries worldwide. The pivotal studies were aimed at studying changes in the efficiency of neutralizing antibodies to the spike protein. However, much less attention was paid to the T-cell response and the presentation of virus peptides by MHC-I molecules. In this study, we compared the features of the HLA-I genotype in symptomatic patients with COVID-19 in the first and third waves of the pandemic. As a result, we could identify the vanishing of carriers of the HLA-A*01:01 allele in the third wave and demonstrate the unique properties of this allele. Thus, HLA-A*01:01-binding immunoprevalent epitopes are mostly derived from ORF1ab. A set of epitopes from ORF1ab was tested, and their high immunogenicity was confirmed. Moreover, analysis of the results of single-cell phenotyping of T-cells in recovered patients showed that the predominant phenotype in HLA-A*01:01 carriers is central memory T-cells. The predominance of T-lymphocytes of this phenotype may contribute to forming long-term T-cell immunity in carriers of this allele. Our results can be the basis for highly effective vaccines based on ORF1ab peptides.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was performed within the framework of the “Creation of Experimental Laboratories in the Natural Sciences Program” at the HSE University. Funding for open access charge: Laboratory for Research on Molecular Mechanisms of Longevity, HSE University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Local Ethics Committee at the Pirogov Russian National Research Medical University (Meeting No. 194 of March 16, 2020, Protocol No. 2020/07), by the Local Ethics Committee at O.M. Filatov City Clinical Hospital (Protocol No. 237 of June 25, 2021), and by the National Research Center for Hematology ethical committee (N 150, 02.07.2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -